A New York woman's HIV stayed gone 18 months after a stem-cell transplant
Published · Researched 2026-09-22
What happened (dated facts)
In a paper published in Cell on March 16, 2023, researchers reported that a New York woman with HIV-1 — the "New York patient" — remained in remission with no viral rebound for at least 18 months after stopping antiretroviral therapy, following a CCR5-delta32/delta32 haplo-cord stem-cell transplant performed to treat her concurrent leukemia. No HIV-1 DNA or RNA and no replication-competent virus were detectable. She was the first mixed-race woman documented in HIV remission. The transplant was a high-risk leukemia treatment, not a scalable HIV therapy, and it must not be framed as a general cure.
Why it is genuinely positive
Each documented case of long-term HIV remission after CCR5-mutant transplant proves that the virus can be driven below detection and held there without drugs — even in a patient whose donor cells only partially engrafted. It is another hard-won data point toward a cure, achieved in a woman of mixed race in a field whose cure cases have been overwhelmingly male and white.
Social pulse
Strong science-press circulation of the Cell paper (March 2023). Targeted Threads searches did not return direct posts about the New York patient in this session. The social layer here is science media rather than viral posts.
Verified quotes
None captured.
Verification
- Tier: 2
- Primary source: Medical Brief summary of the Cell paper (https://www.medicalbrief.co.za/new-york-womans-hiv-in-remission-after-stem-cell-transplant/); background via WHO (https://www.who.int/news/item/24-03-2022-first-case-of-hiv-cure-in-a-woman-after-stem-cell-transplantation-reported-at-croi-2022). Proves: no rebound ≥18 months off ART; no detectable HIV-1 DNA/RNA; CCR5-mutant haplo-cord transplant for leukemia; first mixed-race woman in remission.
- Social sources: health-press layer + targeted Threads searches (direct story posts not captured — noted honestly). Proves: sustained coverage and community relevance via health media.
- Positivity check: documented drug-free remission — genuine, with the risky/not-scalable caveat stated.
Key facts
| Fact | Value | Source | Date |
|---|---|---|---|
| Publication | Cell, March 16, 2023 | Medical Brief | 2023-03-16 |
| Remission | No viral rebound ≥18 months off ART; no detectable HIV-1 DNA/RNA | Cell via Medical Brief | 2023 |
| Treatment | CCR5Δ32/Δ32 haplo-cord stem-cell transplant (for concurrent leukemia) | Cell via Medical Brief | 2023 |
| Significance | First mixed-race woman with documented HIV remission | WHO / Medical Brief | 2023 |
| Caveat | High-risk procedure for leukemia; not a scalable HIV therapy | Research notes | 2026-09-22 |
UNVERIFIED points
- Social-layer posts about the New York patient were not yet observed; tier cannot be finalized until they are.
Sources
- Primary source: Medical Brief summary of the Cell paper ( — retrieval date not recorded
- Primary source: Medical Brief summary of the Cell paper (https://www.medicalbrief.co.za/new-york-womans-hiv-in-remission-after-stem-cell-… — retrieval date not recorded